Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.66 |
| ▸ | ALPI | P09923 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | XIAP | P98170 | 1/20 | 0.66 |
| ▸ | TPH1 | P17752 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | GRB2 | P62993 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL93538 | 1.00 | SLC7A5 (0.67) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL93537 | 1.00 | SLC7A5 (0.67) | SLC7A5PTGS1ALPIPKMXIAP | |
| Ammonia Solution, Strong SCHEMBL18166509 | 0.98 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| Hydrochloric Acid SCHEMBL28673608 | 0.98 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL31021359 | 0.98 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| Hydrochloric Acid SCHEMBL30947766 | 0.98 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| Hydrochloric Acid SCHEMBL28673609 | 0.98 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| Ammonia Solution, Strong SCHEMBL18166510 | 0.98 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| Alanine SCHEMBL20450553 | 0.93 | SLC7A5 (0.59) | SLC7A5PTGS1ALPIPKMXIAP | |
| Iodofalan SCHEMBL28790138 | 0.92 | SLC7A5 (0.57) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000659-A1 | LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN BIOTECH INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12478617-B2 | Lipidated peptide inhibitors of interleukin-23 receptor | JANSSEN BIOTECH, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20240409598-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN BIOTECH INC (US) | 2024-12-12 | — | — | US | disclosed |
| US-20240383954-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH INC (US) | 2024-11-21 | — | — | US | disclosed |
| US-20240352073-A1 | BICYCLIC PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN BIOTECH INC (US) | 2024-10-24 | — | — | US | disclosed |
| US-12097242-B2 | Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-09-24 | — | — | US | disclosed |
| US-12097241-B2 | Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-09-24 | — | — | US | disclosed |
| CN-110637027-B | Modified relaxin polypeptides comprising pharmacokinetic enhancers and uses thereof | 百时美施贵宝公司 | 2024-08-30 | — | — | CN | disclosed |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | JANSSEN BIOTECH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240173309-A1 | LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2024-05-30 | — | — | US | disclosed |
| CN-110637027-A | Modified relaxin polypeptides comprising pharmacokinetic enhancers and uses thereof | 百时美施贵宝公司 | 2019-12-31 | — | — | CN | disclosed |
| US-20190256570-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-08-22 | — | — | US | disclosed |
| US-10294273-B2 | Macrocyclic peptidomimetics for alpha-helix mimicry | UNIVERSITY OF ROCHESTER (US) | 2019-05-21 | — | — | US | disclosed |
| US-10266578-B2 | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-23 | — | — | US | disclosed |
| WO-2018148419-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-08-16 | — | — | WO | disclosed |
| US-20180222960-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2018-08-09 | — | — | US | disclosed |
| US-20170037084-A1 | MACROCYCLIC PEPTIDOMIMETICS FOR ALPHA-HELIX MIMICRY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-02-09 | — | — | US | disclosed |
| US-6833382-B2 | By muta-synthesis using a mutated micro-organism to influence the biosynthesis of at least one of the precursors of group B streptogramines; mutant strain employed is preferably derived from the strain S. pristinaespiralis SP92 | AVENTIS PHARMA S.A. (FR) | 2004-12-21 | — | — | US | disclosed |
| US-20020142947-A1 | STREPTOGRAMINS AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | AVENTIS PHARMA, S.A. | 2002-10-03 | — | — | US | disclosed |
| US-6352839-B1 | PREPARING VIRGINIAMYCINS FROM AN ENGINEERED MICROORGANISMS, HAVING THE ABILITY TO PREVENT BIOSYNTHESIS OF THE PRECURSOR ANTIBIOTIC; THE MICROORGANISM IS CULTURED IN THE PRESENCE OF A SECOND PRECURSOR AND THE STREPTOGRAMIN ANALOG IS RECOVERED | AVENTIS PHARMA S.A. (FR) | 2002-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12097241-B2 | Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides | RXFP2, RXFP1, RXFP4 | SLC7A5 1038/4885PTGS1 1289/4885ALPI 3013/4885 |
| US-10294273-B2 | Macrocyclic peptidomimetics for alpha-helix mimicry | COIL, UACA, NGLY1 | SLC7A5 2220/4885PTGS1 4361/4885ALPI 4623/4885 |
| US-20190256570-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | RXFP2, RXFP1, RXFP4 | SLC7A5 692/4885PTGS1 1214/4885ALPI 2798/4885 |
| US-20240173309-A1 | LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | IL23R, IL1RN, IL36G | SLC7A5 2351/4885PTGS1 1175/4885ALPI 1135/4885 |
| US-20180222960-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | RXFP2, RXFP1, RXFP4 | SLC7A5 692/4885PTGS1 1214/4885ALPI 2798/4885 |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | IL23R, IL1RN, VIP | SLC7A5 3470/4885PTGS1 908/4885ALPI 452/4885 |
| US-20260000659-A1 | LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | IL23R, IL36G, IL15RA | SLC7A5 634/4885PTGS1 1590/4885ALPI 3076/4885 |
| US-20240352073-A1 | BICYCLIC PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | IL23R, IL1RN, IL17A | SLC7A5 1924/4885PTGS1 1206/4885ALPI 2346/4885 |
| US-12478617-B2 | Lipidated peptide inhibitors of interleukin-23 receptor | IL23R, IL1RN, IL36G | SLC7A5 2351/4885PTGS1 1175/4885ALPI 1135/4885 |
| US-20240383954-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | SLC7A5 3470/4885PTGS1 908/4885ALPI 452/4885 |
| US-12097242-B2 | Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides | RXFP2, RXFP1, RXFP4 | SLC7A5 1137/4885PTGS1 994/4885ALPI 3455/4885 |
| US-20240409598-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | IL23R, IL1RN, IL36G | SLC7A5 1072/4885PTGS1 809/4885ALPI 4229/4885 |
| US-20170037084-A1 | MACROCYCLIC PEPTIDOMIMETICS FOR ALPHA-HELIX MIMICRY | COIL, UACA, NGLY1 | SLC7A5 2220/4885PTGS1 4361/4885ALPI 4623/4885 |
| US-20020142947-A1 | STREPTOGRAMINS AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | EMG1, FBL, SMS | SLC7A5 846/4885PTGS1 1729/4885ALPI 1714/4885 |
| US-10266578-B2 | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof | RXFP2, RXFP1, RXFP4 | SLC7A5 692/4885PTGS1 1214/4885ALPI 2798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.